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Abstract
Background:  Inconsistent data exist about the efficacy of probiotics in the treatment of
constipation. Several studies in adults with constipation showed positive effects of probiotics on
constipation. Inconsistent data exist regarding the effect of a single probiotic strain in constipated
children. The aim of this pilot study was to determine the effect of a mixture of probiotics
containing bifidobacteria and lactobacilli in the treatment of childhood constipation.
Methods: Children aged 4–16 years with constipation as defined by the Rome III criteria were
eligible for the study. During a 4 week period, children received a daily mix of 4 × 109 colony
forming units of a probiotic mixture (Ecologic®Relief) containing Bifidobacteria (B.) bifidum, B.
infantis, B. longum, Lactobacilli (L.) casei, L. plantarum and L. rhamnosus. Primary outcome
measures were frequency of bowel movements (BMs) per week and stool consistency. Secondary
outcome measures were number of faecal incontinence episodes per week, abdominal pain and
side effects.
Results: Twenty children, 50% male, median age 8 (range 4–16) were included.
The frequency of BMs per week increased from 2.0 (1.0–5.0) to 4.2 (0.0–16.0) in week 2 (p = 0.10)
and 3.8 (2.1–7.0) in week 4 (p = 0.13). In 12 children presenting with <3 BMs/week, BMs per week
increased significantly from 1.0 (0.0–2.0) to 3.0 (0.0–7.0) in week 2 (p = 0.01) and 3.0 (0.0–10.0) in
week 4 (p = 0.01). The stool consistency was reported as hard in 7 children at baseline, in 4 children
at week 2 (p = 0.23) and in 6 children after 4 weeks of treatment (p = 1.00). A significant decrease
in number of faecal incontinence episodes per week was found in the entire group: 4.0 (0.0–35.0)
to 1.5 (0.0–14.0) in week 2 (p = 0.01) and 0.3 (0.0–7.0) in week 4 (p = 0.001). The presence of
abdominal pain decreased significantly from 45% to 25% in week 2 (p = 0.04) and 20% at week 4 (p
= 0.006). No side effects were reported.
Conclusion: This pilot study shows that a mixture of probiotics, has positive effects on symptoms
of constipation. To confirm these findings, a large randomised placebo controlled trial is required.
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Background
Functional constipation is a common and frustrating phe-
nomenon in children. The prevalence of childhood con-
stipation in the western world is 1–30% [1]. No organic
cause is found in 90% to 95% of those constipated chil-
dren [2]. This functional defecation disorder is character-
ized by infrequent defecation less than three times per
week, more than two episodes of faecal incontinence per
week, the passage of large and painful stools which clog
the toilet and retentive posturing. Upon physical exami-
nation a palpable faecal mass is often found in the abdo-
men and the rectum [3,4].
Childhood constipation is usually treated with a combi-
nation of toilet training, a bowel diary and oral laxatives
such as lactulose or polyethylene glycol (PEG). Laxatives
aim to soften the stools, thereby contributing to a break-
through of the vicious circle of defecation avoidance
caused by pain during defecation. Only 60% of consti-
pated children accomplish successful treatment with laxa-
tives [5]. It is clear that development of other treatment
options is required.
There is growing interest in the use of probiotics in
organic and functional gastrointestinal disorders. Probiot-
ics are live microbial food ingredients which are reported
to be effective in the treatment of IBD, travellers diarrhoea
and constipation [6-9]. Colonic microflora influences the
peristalsis of the colon [10]. Therefore, imbalance in the
colonic microflora has been suggested to play a role in
gastro-intestinal diseases such as constipation. Probiotics,
such as Bifidobacteria (B.) and lactobacilli (L.), both pro-
duce lactic, acetic and other acids resulting in a lowering
of pH in the colon. A lower pH enhances peristalsis of the
colon and subsequently decreases colonic transit time
which is beneficial in the treatment of constipation
[10,11]. The latter hypothesis was confirmed showing a
decrease in colonic transit time in healthy adults consum-
ing B. animalis as supplement [12].
To date, several studies have been performed, mainly in
adults, in order to determine the effects of probiotics on
symptoms of constipation [10-15]. It has been shown that
probiotic strains, such as L. shirota and the B. infantis,
increase defecation frequency and soften stools in adults
with constipation and IBS [13,16]. A recent study in chil-
dren with constipation showed an increase in defecation
frequency and a decrease in abdominal pain using the
strain L. rhamnosus [9]. In contrast to the latter study how-
ever, the probiotic strain Lactobacillus GG did not have an
additional positive effect on constipation symptoms,
when used as an adjunctive therapy with lactulose [14].
In constipated elderly, two different strains the Lactobacil-
lus rhamnosus and Propionibacterium freudenreichii
resulted in a small but significant increase in defecation
frequency, whereas the use of a single strain did not affect
defecation frequency [17].
The interpretation of these clinical trials is difficult to
compare due to the differences in endpoints, variations in
probiotics used, dose and strains. Nonetheless, a recent
review suggested that overall, sufficient evidence is availa-
ble to warrant further evaluation [18].
Therefore we hypothesized that a combination of several
strains of bifidobacteria and lactobacilli might be effective
in the treatment of childhood constipation. In a pilot
study, we aimed to determine the therapeutic effect of a
combination of probiotics strains, containing the bifido-
bacteria B. bifidus, B. infantis and B. longum and the lactoba-
cilli L. casei, L. plantarum and L. rhamnosus, on childhood
constipation.
Methods
Subjects
Children between 4 to 16 years of age referred to the out-
patient clinic of the Emma Children's Hospital in Amster-
dam, the Netherlands, with constipation were eligible for
study entry. Childhood constipation was defined by the
Rome III criteria as having at least 2 out of 6 of the follow-
ing symptoms: bowel movements <3 times/week; faecal
incontinence >2 times/week; large amounts of stools
obstructing the toilet once in 10 days; painful defecation;
withholding behaviour; palpable abdominal or rectal
mass on physical examination [4]. Exclusion criteria were
the use of any oral laxative < 4 weeks before intake, mental
retardation, metabolic disease, functional non-retentive
incontinence, and a history of gastro-intestinal surgery.
All children older than 12 years and/or parents gave
informed consent. This pilot was approved by the medical
ethical committee of the Academic Medical Centre of
Amsterdam.
Study design
Seven days prior to baseline assessment and during the
treatment period all children recorded frequency of bowel
movements, the number of faecal incontinence episodes,
stool consistency, abdominal pain, flatulence and pain
during defecation as well as adverse effects such as vomit-
ing and diarrhoea in a standardized bowel diary.
At baseline assessment, a medical history and information
on the current defection pattern was collected. Addition-
ally, a physical examination including a rectal digital
exam was performed to assess whether an abdominal or
rectal faecal mass was present.
Before start of the probiotics treatment, all children
received once daily for 3 days a rectal enema (Klyx:Nutrition Journal 2007, 6:17 http://www.nutritionj.com/content/6/1/17
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sodium-dioctylsulfosuccinate and sorbitol) in order to
accomplish rectal disimpaction. After rectal disimpaction,
children were administrated a daily probiotics mixture of
4 × 109 colony forming units (CFU), containing Bifidobac-
teria (B.) bifidum, B. infantis, B. longum, Lactobacilli (L.)
casei, L. plantarum and L. rhamnosus (Ecologic®Relief, Win-
clove Bio Industries BV, The Netherlands) for 4 weeks. Dur-
ing the treatment period children were instructed to start
toilet training. Toilet training consisted of sitting on the
toilet 3 times per day for 5 minutes after each meal with
the intention of trying to defecate. The use of laxatives was
not allowed during the short treatment period.
Evaluation was conducted during visits to the outpatient
clinic at 2 and 4 weeks after start of treatment. During each
visit the physician assessed the patient's daily bowel diary
and examined the child.
Outcome measures
Primary outcome measures were frequency of bowel
movements per week and stool consistency. Stool consist-
ency was rated by the patients as hard, normal or watery.
Secondary outcome measures were number of faecal
incontinence episodes per week, presence of abdominal
pain and incidence of adverse effects such as vomiting and
diarrhoea.
Analysis
Descriptive statistical measures were calculated for base-
line characteristics using SPSS version 12.0.1 statistical
software (SPSS Inc, Chicago, Ill). Change of frequency of
bowel movements and faecal incontinence was assessed
using the non-parametric paired Wilcoxon test. For the
analysis of change of stool consistency, the Mc Nemar test
was used. For the comparison of abdominal pain between
baseline and the evaluation time points, the Wilcoxon
rank test was used. All continuous values were expressed
as median (range). A p- value < 0.05 was considered sig-
nificant.
Results
Between February 2006 and July 2006, 20 children were
enrolled into this pilot study and all patients completed
the study. Baseline characteristics are summarized in table
1. In 85% of the children, onset of constipation symp-
toms was between 0 to 4 years of age.
The frequency of bowel movements (BMs) per week
increased from 2.0 (1.0–5.0) to 4.2 (0.0–16.0) in week 2
(p = 0.10) and 3.8 (2.1–7.0) in week 4 (p = 0.13) (figure
1). In 12 children presenting with <3 BMs per week, BMs
per week increased significantly from 1.0 (0.0–2.0) to 3.0
(0.0–7.0) in week 2 (p = 0.01) and 3.0 (0.0–10.0) in week
4 (p = 0.009) (figure 2).
The stool consistency was reported as hard in 7 children at
baseline, in 4 children at week 2 (p = 0.23) and in 6 chil-
dren at week 4 (p = 1.00). At week 4, hard stools appeared
in 5 children who also had hard stools at baseline. One
child with normal stools at baseline, reported hard stools
only at the end of the study. Two of the 7 children who
presented with hard stools, reported normal stools at the
end of the study.
The number of faecal incontinence episodes per week
decreased significantly from 4.0 (0.0–35.0) to 1.5 (0.0–
14.0) in week 2 (p = 0.007) and 0.3 (0.0–7.0) in week 4
(p = 0.001) (figure 3).
The presence of abdominal pain decreased significantly
from 45% (n = 9) to 25% (n = 5) in week 2 (p = 0.04) and
20% (n = 4) at week 4 (p = 0.006). There were no side
effects such as vomiting, bloating and increased flatulence
during the study period.
Discussion
This pilot study showed that a probiotics mixture contain-
ing different strains of bifidobacteria and lactobacilli,
increases the frequency of bowel movements in consti-
pated children presenting with a defecation frequency of
less than 3 times per week. This probiotic mixture was also
effective in decreasing the number of faecal incontinence
episodes and in reducing the presence of abdominal pain.
No significant changes in stool consistency were found.
Given their safety profile, probiotics could be an attractive
compound to manipulate gastrointestinal motility in con-
stipated children [19]. However, exact mechanisms
underlying enhancement of gastrointestinal transit are
not yet unravelled. Based on the results of our pilot study
we hypothesise that a mixture of bifidobacteria and lacto-
bacilli producing lactic, acetic and other acids resulting in
a lowering of pH in the colon are effective in enhancing
motility of the colon, subsequently leading to a decrease
in colonic transit time. A large randomized placebo con-
trolled trial is necessary to confirm these findings.
In this study, we found that administration of a mixture of
probiotics had a positive effect on frequency of bowel
movements and consequently leading to a decrease in fae-
cal incontinence episodes. In contrast to our findings,
Banaszkiewicz showed no additional effect of lactobacillus
GG (LGG) to placebo in children with constipation who
were all treated with lactulose. The authors suggested that
the probiotic strain LGG may not provide clinical benefits
in the treatment of constipation. Furthermore they
assumed that the failure of LGG to provide synergistic
effects (with lactulose) occurred despite the tempting
notion that the concurrent use of lactulose with proven
probiotic properties (ie, it promotes growth of lactobacilliNutrition Journal 2007, 6:17 http://www.nutritionj.com/content/6/1/17
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in the colon) should enhance the therapeutic effects of
LGG. A second study in which a group receives LGG
alone, is needed to more directly examine this issue.
It has been assumed that probiotics soften the stools by
stimulating water and electrolyte secretion [20-22]. How-
ever, we were not able to show a significant softening of
stools after 4 weeks of treatment. As only a minority of
children (35%) had hard stools at baseline, it is necessary
to investigate whether this probiotic mixture has a posi-
tive effect on hard stools in a larger randomised controlled
trial.
A significant decrease in abdominal pain was found after
4 weeks of treatment with the probiotics mixture. This is
in accordance with one paediatric study and several adult
studies performed in irritable bowel syndrome (IBS)
patients with abdominal pain/discomfort, distension/
bloating and difficult defecation [9,23,24]. A recent rand-
omized placebo controlled trial conducted in 360 women
with IBS showed that the strain B. infantis was associated
with significant improvement of both abdominal pain
and the subjects' global assessment of symptoms [16].
This positive effect on abdominal pain occurred irrespec-
tive of any effect on stool frequency which indicates that
the observed effect was not attributable to either a laxative
or anti-diarrhoeal effect. It has been suggested previously
that abdominal pain and bloating may decrease as a con-
sequence act of probiotics diminishing visceral hypersen-
sitivity by its anti-inflammatory effect on the enteric
mucosa [25].
No side effects of the probiotics were found in our study.
This is in accordance with literature about the safety of
probiotics [19,26]. The safe use of especially bifidobacte-
ria is supported by the long historical consumption of fer-
mented milk and growing knowledge about
bifidobacteria taxonomy and physiology. Furthermore,
studies performed with lactobacilli and bifidobacteria
showed to be well tolerated in adults and children
[6,9,14], [26-28].
The interpretation of clinical trials of probiotic strains in
functional gastrointestinal disorders is complicated by
Table 1: Baseline characteristics
Baseline characteristics
Number of subjects 20
Age in years 8 (4–16)
Sex (male) 10
Time of constipation before intake (years) 3.5 (0.3–6.5)
Treatment time before intake (months) 12 (0–48)
Bowel habits, n (%)
• Bowel movements < 3/week 12 (60%)
• Faecal incontinence ≤ 2/week 1 (5%)
• Faecal incontinence > 2/week 15 (80%)
• Large amounts of stools 12 (60%)
Stool consistency, n (%)
• Hard stools 7 (35%)
• Normal stools 13 (65%)
• Watery stools 0
Painful defecation, n (%)
• No pain 7 (35%)
• Sometimes painful 7 (35%)
• Always painful 6 (30%)
Abdominal pain, n (%)
• No abdominal pain 3 (15%)
• Sometimes abdominal pain 8 (40%)
• Often abdominal pain 9 (45%)
Physical examination, n (%)
• Abdominal scybala 4 (20%)
• Rectal scybala 4 (20%)
• Anal Fissures 0Nutrition Journal 2007, 6:17 http://www.nutritionj.com/content/6/1/17
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several factors. Results between studies are difficult to
compare due to differences in endpoints, variations in
probiotics dose and strains. Whereas one group uses mix-
tures of probiotics, others use single isolates, making it
difficult to determine what were the active moieties
[29,30]. Nonetheless, a recent review suggested that over-
all, sufficient evidence is available to warrant further eval-
uation [18].
In conclusion, this non randomized non placebo control-
led pilot study evaluating the effect of a mixture of probi-
otics, showed beneficial effects on symptoms of
constipation and a decrease of abdominal pain. Therefore
a randomised placebo controlled trial is now required to
confirm these data.
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